{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-038517","form_type":"8-K/A","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.885088+00:00","generated_at":"2026-06-06T00:07:11.309905+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vanda files financials for PONVORY acquisition; product line had $553.7M loss in FY2023 on $17.8M sales","bullets":["Purchase price $100M for U.S./Canadian rights of PONVORY (ponesimod) from Johnson & Johnson.","FY2023 net sales $17.8M, up from $3.9M in prior year; direct expenses $571.6M.","Non-cash impairment of $426.1M on intangible asset, reducing net book value to $36.8M.","Direct expenses exceeded sales by $553.7M; prior year excess was $160.3M.","Vanda also filed unaudited pro forma condensed combined financials for year ended Dec 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-038517","json":"https://secwatch.observer/filing/0001193125-24-038517.json","markdown":"https://secwatch.observer/filing/0001193125-24-038517.md","text":"https://secwatch.observer/filing/0001193125-24-038517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000119312524038517/0001193125-24-038517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000119312524038517/d620689d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:07:11.309905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}